ROME-Italian scientist Barbara Ensoli, MD, said an AIDS vaccine she helped develop is reaching an important stage.
Soon, scientists will begin testing the vaccine on humans. In preliminary tests on monkeys, Ensoli had a 71% success rate.
The Italian vaccine is different from others under the microscope because it has been designed to attack the virus from growing in the body. Other vaccines in development are focusing on boosting the immune system against the virus.
Ensoli is focusing on a key aspect of the virus, the TAT protein. She discovered that the TAT protein is responsible for the virus taking root and is released by cells after infection. By controlling this protein, Ensoli hopes to prevent virus replication.
For HIV positive patients, the vaccine should also work to block virus replication.
HIV remains a difficult virus to control because of its ability to adapt and change between geographical areas, from person to person, or even within the same person. There is no specific envelope protein to attack, as in other viral vaccinations.
Ensoli hopes her vaccine will work against all strains of HIV. She is currently researching infected individuals from Italy, Uganda, and South Africa who are infected with different strains. Yet, Ensoli says each strain has the same TAT protein.
The first stage of human testing, scheduled to begin this summer, will last six months, with six months following to study the results.
The Italian doctor says she dos not expect the vaccine to be available publicly for five to seven years.
More than 21 million people have died form AIDS. There are 36 million people infected today, with more than 25 million of those living in sub-Saharan Africa.
Information from Reuters
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.